↓ Skip to main content

Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series

Overview of attention for article published in Journal of Neuro-Oncology, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#13 of 1,702)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
4 news outlets
twitter
1 tweeter

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
33 Mendeley
Title
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Published in
Journal of Neuro-Oncology, May 2017
DOI 10.1007/s11060-017-2466-0
Pubmed ID
Authors

Marc C. Chamberlain, Bryan T. Kim

Abstract

A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52-72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence. Patients were treated with nivolumab only (3 mg/kg) once every 2 weeks at second recurrence. One cycle of nivolumab was defined as 2 treatments. Neurological evaluation was performed bi-weekly and neuroradiographic assessment every 4 weeks. A total of 37 treatment cycles (median 2) were administered of nivolumab in which there were 14 Grade 2 adverse events (AEs) and Grade 3 AEs in two patients. No Grade 4 or 5 AEs were seen. Following 1 month of nivolumab, seven patients demonstrated progressive disease and discontinued therapy. No patient demonstrated a response though nine patients demonstrated neuroradiographic stable response. Survival in the entire cohort ranged from 2 to 6 months with a median of 3.5 months (CI 2.8, 4.2). Median and 6-month PFS at 6 months was 2.0 months (range 1-5 months; CI 1.3, 2.7) and 0% respectively. Nivolumab salvage therapy demonstrated no survival advantage in patients with recurrent bevacizumab refractory GBM emphasizing a continued unmet need in neuro-oncology.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 5 15%
Researcher 5 15%
Student > Ph. D. Student 5 15%
Student > Postgraduate 4 12%
Student > Bachelor 4 12%
Other 10 30%
Readers by discipline Count As %
Medicine and Dentistry 15 45%
Unspecified 7 21%
Agricultural and Biological Sciences 4 12%
Neuroscience 2 6%
Immunology and Microbiology 2 6%
Other 3 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2017.
All research outputs
#398,547
of 11,823,343 outputs
Outputs from Journal of Neuro-Oncology
#13
of 1,702 outputs
Outputs of similar age
#18,368
of 268,929 outputs
Outputs of similar age from Journal of Neuro-Oncology
#2
of 87 outputs
Altmetric has tracked 11,823,343 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,702 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,929 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.